Mark Varney of Neurolixis joined us at World Orphan Drug Congress USA 2015 to present about ‘ NLX-101 for the Treatment of Rett Syndrome’.
Download the presentation now to learn about:
- Rett Syndrome: Key Facts
- Pleiotropy in Rett Syndrome
- NLX-101: A selective 5-HT 1A receptor “biased agonist”
…and much more!
Get your copy here!
To find out more about NLX-101 as a treatment of Rett Syndrome , join us at World Orphan Drug Congress USA 2016 April 20-22 in Washington, DC.